Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy

  • R. Gurny
  • J. E. Ryser
  • C. Tabatabay
  • M. Martenet
  • P. Edman
  • O. Camber
Clinical Investigations


The aim of the present study was to quantify in man the distribution and clearance of two aqueous sodium hyaluronate (SH) solutions of 0.125% and 0.250% after the administration of 25 μl onto the cornea. Isotonic phosphate buffer (PB) was used as a reference instillation. No systemic or local medication was given to the seven 18- to 30-year-old, healthy male volunteers. A detailed evaluation of the anterior segment of the eye, as well as a Schirmer test and a break-up time measurement, yielded results within the normal range. The clearance of 0.125% and 0.250% SH solutions radiolabelled with sodium pertechnetate Tc-99m was measured by gamma scintigraphy and compared with that of a PB solution tagged with the same radiolabel. There was no statistically significant difference between the quantities of 0.125% SH and PB solutions remaining in the precorneal space at 20 min (paired t-test,P=0.78,n=7). However, in comparing the 0.250% SH with the PB solution, we observed a statistically significant difference (P=0.01,n=7) in the amount remaining in the precorneal space after the same interval. Actually, 53% of the radiolabelled 0.250% SH solution remained on the cornea as compared with 30% for the 0.125% SH solution and 18.3% for the PB solution. These results suggest that an SH solution of 0.250% might have a prolonged residence time on the precorneal surface, and that SH could therefore be used as an additive in various drug-release systems for the eye.


Phosphate Buffer Solution Hyaluronate Male Volunteer Anterior Segment Aqueous Sodium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barett TW (1976) The molecular dynamics of hyaluronates in solution. Biosystems 8:103–109Google Scholar
  2. 2.
    Camber O, Lundgren P (1985) Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharm Suec 22:315–320Google Scholar
  3. 3.
    Camber O, Edman P, Gurny R (1987) Influence of sodium hyaluronate on the miotic effect of pilocarpine in rabbits. Curr Eye Res 6:779–783Google Scholar
  4. 4.
    Gurny R, Ibrahim H, Aebi A, Buri P, Wilson CG, Washington N, Edman P, Camber O (1987) Design and evaluation of controlled release systems for the eye. J Controlled Release 6:367–373Google Scholar
  5. 5.
    Norn SM (1981) Perioperative protection of cornea and conjunctiva. Acta Ophthalmol 59:587–594Google Scholar
  6. 6.
    Polack MF, McNiece MT (1982) The treatment of dry eyes with Na hyaluronate (Healon®). Cornea 1:133–136Google Scholar
  7. 7.
    Robinson JR (1989) Ocular drug delivery mechanism(s) of corneal drug transport and mucoadhesive delivery systems. STP Pharma 5:839–846Google Scholar
  8. 8.
    Rozier A, Mazuel C, Grove J, Plazonnet B (1989) Gelvrite: a novel, ion-actived, in-situ gelling polymer for ophthalmic vehicoles. Effect on bioavailability of timolol. Int J Pharm 57:163–168Google Scholar
  9. 9.
    Saettone MF, Giannaccini B, Delmonte G, Campigli V, Tota G, La Marca F (1988) Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans. Int J Pharm 43:67–76Google Scholar
  10. 10.
    Sand BB, Marner K, Norn MS (1989) Sodium hyaluronate in the treatment of kerato-conjunctivitis sicca. Acta Ophthalmol 67:181–183Google Scholar
  11. 11.
    Saric D, Reim M (1984) Behandlung von Verätzungen des vorderen Augenabschnitts mit hochpolymeren Na-Hyaluronat (Healon®). Fortschr Ophthalmol 81:588–591Google Scholar
  12. 12.
    Tabatabay C (1984) Utilisation du Healon® lors d'éépithélialisation cornéenne défectueuse. J Fr Ophtalmol 7:755Google Scholar
  13. 13.
    Tabatabay C (1985) Instillation d'acide hyaluronique à 0.1% lors de kératite sèche sévère. J Fr Ophthalmol 8:513Google Scholar
  14. 14.
    Tabatabay C, Ryser JE, Gurny R, Edman P, Camber O (1989) Precorneal residence time of sodium hyaluronate solutions measured by gamma scintigraphy. Invest Ophthalmol Vis Sci [Suppl] 30:248Google Scholar
  15. 15.
    Wysenbeek YS, Loya N, Ben Sira I, Ophir I, Ben Shaul Y (1988) The effect of sodium hyaluronate on the cornea epithelium. Invest Ophthalmol Vis Sci 29:194–199Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. Gurny
    • 1
  • J. E. Ryser
    • 2
  • C. Tabatabay
    • 3
  • M. Martenet
    • 1
  • P. Edman
    • 4
  • O. Camber
    • 4
  1. 1.Department of Pharmaceutical TechnologyUniversity of GenevaGeneva 4Switzerland
  2. 2.Department of Nuclear MedicineUniversity Hospital of GenevaSwitzerland
  3. 3.Department of OphthalmologyUniversity Hospital of GenevaSwitzerland
  4. 4.Department of Pharmaceutical R & DPharmacia-Leo Therapeutics ABUppsalaSweden

Personalised recommendations